---

---

symbols : Gsk    crawled time : 13:00   

save search

---

CureVac meldet Fortschritte in klinischen Phase-2-Entwicklungsprogrammen für COVID-19 und die saisonale Grippe in Zusammenarbeit mit GSK
Published: 2023-11-01 (Crawled : 13:00) - curevac.com
GLAXF | $20.2 510 |

Health Technology

| 12.22% | O: -1.62% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| 10.92% | O: -4.06% H: 1.9% C: 0.96%
CVAC | News | $2.42 -0.82% 81K |

Health Technology

| -53.96% | O: 0.19% H: 3.95% C: -1.32%
covid-19 phase 2

---

GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Published: 2023-06-21 (Crawled : 13:00) - biospace.com/
GSK | $39.685 1.06% 380K |

Health Technology

| 14.38% | O: 0.55% H: 1.09% C: 0.98%
AGEN | $5.62 13.08% 510K |

Health Technology

| 165.78% | O: 0.0% H: 2.67% C: -1.6%
respiratory positive rsv virus

---

Renal Anemia Therapeutics Market size to grow by USD 1.97 billion from 2021 to 2026, Driven by the presence of a large pool of CKD patients - Technavio
Published: 2023-04-07 (Crawled : 13:00) - prnewswire.com
GSK | $39.685 1.06% 380K |

Health Technology

| Email alert Add to watchlist
AZNCF | $138.24 800 |

Health Technology

| Email alert Add to watchlist
AZN | $68.545 0.27% 1.2M |

Health Technology

| Email alert Add to watchlist
AMGN | $265.32 0.98% 550K |

Health Technology

| Email alert Add to watchlist
PSORF | $13.01 -8.53% 110 |

Consumer Services

| Email alert Add to watchlist
GLAXF | $20.2 510 |

Health Technology

| Email alert Add to watchlist
renal anemia therapeutics market

---

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 510 |

Health Technology

| 14.64% | O: 2.04% H: 0.0% C: -3.67%
PFE A | $25.615 0.89% 9.9M |

Health Technology

| -41.63% | O: -1.26% H: 2.97% C: 2.7%
GSK | $39.685 1.06% 380K |

Health Technology

| 12.76% | O: 0.85% H: 0.31% C: -0.45%
BHVN | News 0 d | $40.43 -4.1% 560K |

Health Technology

| 126.91% | O: -0.48% H: 4.49% C: 3.24%
BNTX | $87.02 0.99% 140K |

Health Technology

| -38.66% | O: -1.74% H: 4.84% C: 3.88%
BEAM | $24.35 0.17% 280K |

Health Technology

| -38.95% | O: 0.21% H: 4.84% C: 2.99%
financial results

---

Insights on the Substance Abuse Treatment Global Market to 2030 - by Treatment and Region
Published: 2023-01-30 (Crawled : 13:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| 13.67% | O: -2.59% H: 3.12% C: 1.79%
GSK | $39.685 1.06% 380K |

Health Technology

| 12.18% | O: 0.74% H: 0.2% C: -1.24%
ALKS | $23.66 -0.42% 290K |

Health Technology

| -18.13% | O: 0.07% H: 0.83% C: -0.86%
treatment global market

---

The Worldwide Manual Toothbrush Industry is Expected to Reach $8.1 Billion by 2028
Published: 2023-01-17 (Crawled : 13:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| 15.99% | O: -0.95% H: 3.65% C: 3.19%
UNLYF | $47.95 740 |

Consumer Non-Durables

| -5.42% | O: 1.38% H: 0.0% C: 0.0%
UL | $47.19 0.73% 2.3M |

Consumer Non-Durables

| -9.23% | O: -0.68% H: 0.53% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| 11.93% | O: 0.31% H: 0.62% C: 0.2%
expected

---

Outlook on the Pharmaceutical Drugs Global Market to 2027: Look at the Changing Structure of the Pharma and Healthcare Industry
Published: 2023-01-03 (Crawled : 13:00) - prnewswire.com
ENDPQ | $0.0006 3.4K |

n/a

| -94.35% | O: -1.13% H: 28.57% C: 19.0%
CSLLY | $86.918 60K |

n/a

| -9.95% | O: -3.93% H: 2.17% C: 1.75%
MNK | $0.3402 -0.06% 540K |

n/a

| -94.75% | O: 3.1% H: 0.0% C: -2.75%
GLAXF | $20.2 510 |

Health Technology

| 15.53% | O: -0.2% H: 2.06% C: 2.06%
SNYNF | News | $92.7 600K |

Health Technology

| -3.71% | O: 1.09% H: 0.54% C: 0.54%
UCBJY | $63.676 7.2K |

Manufacturing

| 63.03% | O: 1.0% H: 0.0% C: -0.26%
ALPMY | $9.47 520K |

Manufacturing

| -38.39% | O: 3.43% H: 0.0% C: -2.93%
VTRS | $11.2 0.72% 1M |

Health Technology

| -0.09% | O: 0.54% H: 2.5% C: 1.7%
NVO | $123.43 0.55% 1.4M |

Health Technology

| -7.99% | O: 1.43% H: 0.84% C: -0.23%
NVS | $93.815 1.35% 410K |

Health Technology

| 2.6% | O: 0.42% H: 1.35% C: 1.22%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -17.95% | O: -0.28% H: 1.26% C: 1.15%
GSK | $39.685 1.06% 380K |

Health Technology

| 12.69% | O: -0.57% H: 1.35% C: 1.0%
BHC | $8.655 0.64% 750K |

Health Technology

| 39.17% | O: 0.48% H: 3.96% C: -0.48%
ABBV | News | $164.91 0.15% 1.2M |

Health Technology

| 2.2% | O: 0.27% H: 0.6% C: 0.21%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -5.89% | O: 0.16% H: 0.0% C: 0.0%
AMGN | $265.32 0.98% 550K |

Health Technology

| 0.87% | O: -0.67% H: 0.66% C: 0.3%
pharma global market

---

Consumer Healthcare Global Market Report 2022
Published: 2022-09-20 (Crawled : 13:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| 30.32% | O: -6.97% H: 7.7% C: -0.76%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -12.55% | O: -0.33% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| 28.65% | O: -0.71% H: 0.2% C: -0.23%
ABT | News | $107.24 1.87% 2M |

Health Technology

| 2.22% | O: -1.25% H: 0.23% C: -0.47%
SNY | News | $46.34 2.09% 620K |

Health Technology

| 12.86% | O: -1.18% H: 0.0% C: 0.0%
global report market

---

Human Papillomavirus Vaccine (HPV) Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR: Allied Market Research
Published: 2022-07-21 (Crawled : 13:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| -1.32% | O: 6.64% H: 0.0% C: -4.08%
SNYNF | News | $92.7 600K |

Health Technology

| -11.58% | O: -2.38% H: 0.0% C: 0.0%
AZNCF | $138.24 800 |

Health Technology

| 4.15% | O: 0.15% H: 0.0% C: -3.5%
NVS | $93.815 1.35% 410K |

Health Technology

| 10.52% | O: 0.09% H: 1.9% C: 1.89%
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| -15.81% | O: -1.18% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -4.81% | O: 1.3% H: 0.38% C: -0.38%
XBIO | $4.14 61 |

Health Technology

| -95.36% | O: 0.41% H: 7.44% C: -2.71%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -10.57% | O: -3.38% H: 0.0% C: 0.0%
INO 3 d | $9.755 -4.36% 110K |

Health Technology

| 357.4% | O: 0.0% H: 1.35% C: -5.83%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 3.76% | O: -2.75% H: 2.31% C: 2.15%
research vaccine market

---

Pfizer Provides Update on Ownership Interest in Haleon
Published: 2022-06-01 (Crawled : 13:00) - biospace.com/
PFE A | $25.615 0.89% 9.9M |

Health Technology

| -52.19% | O: -0.02% H: 0.0% C: 0.0%
MS | News 0 d | $91.305 1.16% 1.7M |

Finance

| 6.38% | O: 1.51% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -9.82% | O: -0.39% H: 0.05% C: -1.6%

---

Oak Hill Bio Announces Formation of Board of Directors
Published: 2022-04-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.255 0.72% 200K |

Health Technology

| -11.21% | O: 0.07% H: 0.47% C: -0.4%
NVO | $123.43 0.55% 1.4M |

Health Technology

| 2.96% | O: -3.41% H: 1.22% C: 0.49%
GSK | $39.685 1.06% 380K |

Health Technology

| -15.65% | O: -0.36% H: 0.0% C: 0.0%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -21.37% | O: -3.25% H: 0.0% C: 0.0%

---

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
Published: 2022-02-07 (Crawled : 13:00) - biospace.com/
PFE A | $25.615 0.89% 9.9M |

Health Technology

| -52.03% | O: 0.4% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -11.8% | O: -0.29% H: 0.7% C: 0.49%
health thc drug hiv

---

908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer
Published: 2022-01-07 (Crawled : 13:00) - biospace.com/
MASS | $5.73 2.32% 31K |

| -75.84% | O: -10.29% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -9.05% | O: 0.05% H: 0.0% C: 0.0%
ces device cel media

---

Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 510 |

Health Technology

| -3.64% | O: 1.8% H: 0.0% C: -0.31%
GSK | $39.685 1.06% 380K |

Health Technology

| -8.08% | O: 0.93% H: 0.0% C: 0.0%
VIR | $8.02 0.75% 140K |

Health Technology

| -74.54% | O: 4.66% H: 0.0% C: 0.0%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -11.58% | O: -0.66% H: 0.0% C: 0.0%
covid treatment phase 3 trial

---

PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 510 |

Health Technology

| -3.9% | O: 1.14% H: 0.94% C: -1.98%
ALPMY | $9.47 520K |

Manufacturing

| -45.51% | O: -1.58% H: 0.42% C: 0.24%
VTRS | $11.2 0.72% 1M |

Health Technology

| -16.89% | O: 3.46% H: 0.7% C: -0.09%
PFE A | $25.615 0.89% 9.9M |

Health Technology

| -42.4% | O: 2.06% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -6.58% | O: 1.16% H: 0.75% C: -0.19%
LLY | $731.1 -1.99% 1M |

Health Technology

| 194.17% | O: -1.55% H: 0.0% C: 0.0%
BNTX | $87.02 0.99% 140K |

Health Technology

| -69.41% | O: 0.13% H: 3.09% C: 2.62%
ARVN | $34.04 -0.73% 86K |

Health Technology

| -61.51% | O: 1.4% H: 4.09% C: 4.07%
results

---

Alnylam Announces Planned CEO Leadership Transition
Published: 2021-10-28 (Crawled : 13:00) - biospace.com/
GLAXF | $20.2 510 |

Health Technology

| 2.02% | O: 1.06% H: 3.7% C: 1.85%
GSK | $39.685 1.06% 380K |

Health Technology

| -2.03% | O: 2.23% H: 2.11% C: 1.94%
ALNY | News | $146.34 0.81% 64K |

Health Technology

| -24.06% | O: -11.56% H: 2.01% C: -4.1%
ceo leo

---

Adaptive Phage Therapeutics Adds Jesse L. Goodman, M.D., M.P.H., to its Board of Directors
Published: 2021-09-14 (Crawled : 13:00) - biospace.com/
GSK | $39.685 1.06% 380K |

Health Technology

| -0.4% | O: -0.1% H: 0.31% C: -0.88%

---

Global Haemophilus influenzae Type B Infections 2021 Pipeline Guide and Drugs In Development
Published: 2021-08-19 (Crawled : 13:00) - prnewswire.com
GSK | $39.685 1.06% 380K |

Health Technology

| -6.05% | O: -1.04% H: 0.8% C: 0.24%
drug influenza injection infections

---

Global CNS Therapeutics Market to Reach $132.1 Billion by 2024
Published: 2021-08-13 (Crawled : 13:00) - prnewswire.com
NVS | $93.815 1.35% 410K |

Health Technology

| 0.23% | O: 0.6% H: 0.0% C: 0.0%
GSK | $39.685 1.06% 380K |

Health Technology

| -4.02% | O: 0.8% H: 0.0% C: 0.0%
ABBV | News | $164.91 0.15% 1.2M |

Health Technology

| 42.82% | O: 0.14% H: 0.0% C: 0.0%
SNY | News | $46.34 2.09% 620K |

Health Technology

| -11.3% | O: 0.43% H: 0.0% C: 0.0%
NBIX M | $132.23 -0.23% 96K |

Health Technology

| 53.7% | O: 0.67% H: 0.0% C: 0.0%
AZN | $68.545 0.27% 1.2M |

Health Technology

| 18.8% | O: 0.57% H: 0.0% C: 0.0%
ALKS | $23.66 -0.42% 290K |

Health Technology

| -17.96% | O: 0.0% H: 0.0% C: 0.0%
therapeutics

---

Worldwide End Stage Renal Disease Industry to 2026 - High Focus on Technology Presents Opportunities
Published: 2021-07-05 (Crawled : 13:00) - prnewswire.com
SNY | News | $46.34 2.09% 620K |

Health Technology

| Email alert Add to watchlist
GSK | $39.685 1.06% 380K |

Health Technology

| Email alert Add to watchlist
MDT | $79.49 0.38% 1.4M |

Health Technology

| Email alert Add to watchlist
BMY | $48.56 0.54% 1.8M |

Health Technology

| Email alert Add to watchlist
NVS | $93.815 1.35% 410K |

Health Technology

| Email alert Add to watchlist
AMGN | $265.32 0.98% 550K |

Health Technology

| Email alert Add to watchlist
disease renal technology

---

Gainers vs Losers

79%

21%

Top 10 Gainers

AGBA | News | $1.22 205.0% 86M |

Finance

EGOX | $0.0606 68.33% 250M |

NVFY | $3.45 63.51% 20M |

Consumer Durables

ZCMD | $1.98 36.55% 27M |

Commercial Services

CHRO | $1.66 35.51% 70K |

n/a

INDO | $5.43 33.09% 10M |

Energy Minerals

PAPL | $2.07 26.22% 550K |

RWOD | $10.08 26.05% 5.6M |

n/a

AULT | $0.304 25.57% 47M |

Manufacturing

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

---

Your saved searches

---